 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
20 June 2006 | Volume 144 Issue 12 | Pages 904-912
Background: Long-acting ß-agonists may increase the risk for fatal and nonfatal asthma exacerbations.
Purpose: To assess the risk for severe, life-threatening, or fatal asthma exacerbations associated with long-acting ß-agonists.
Data Sources: English- and non–English-language searches of MEDLINE, EMBASE, and Cochrane databases; the U.S. Food and Drug Administration Web site; and references of selected reviews through December 2005.
Study Selection: Randomized, placebo-controlled trials that lasted at least 3 months and evaluated long-acting ß-agonist use in patients with asthma. All trials allowed the use of as-needed short-acting ß-agonists.
Data Extraction: Outcomes measured were Peto odds ratio (OR) and risk difference of severe exacerbations requiring hospitalization, life-threatening exacerbations requiring intubation and ventilation, and asthma-related deaths. The OR for asthma-related deaths was obtained from the Salmeterol Multi-center Asthma Research Trial (SMART).
Data Synthesis: Pooled results from 19 trials with 33 826 participants found that long-acting ß-agonists increased exacerbations requiring hospitalization (OR, 2.6 [95% CI, 1.6 to 4.3]) and life-threatening exacerbations (OR, 1.8 [CI, 1.1 to 2.9]) compared with placebo. Hospitalizations were statistically significantly increased with salmeterol (OR, 1.7 [CI, 1.1 to 2.7]) and formoterol (OR, 3.2 [CI, 1.7 to 6.0]) and in children (OR, 3.9 [CI, 1.7 to 8.8]) and adults (OR, 2.0 [CI, 1.1 to 3.9]). The absolute increase in hospitalization was 0.7% (CI, 0.1% to 1.3%) over 6 months. The risk for asthma-related deaths was increased (OR, 3.5 [CI, 1.3 to 9.3]), with a pooled risk difference of 0.07% (CI, 0.01% to 0.1%).
Limitations: The small number of deaths limited the reliability in assessing this risk, and 28 studies did not report information on the outcomes of interest.
Conclusions: Long-acting ß-agonists have been shown to increase severe and life-threatening asthma exacerbations, as well as asthma-related deaths.
Editors' Notes
Context
Contribution
Cautions
—The Editors
Author and Article Information
From Santa Clara Valley Medical Center, San Jose, California, and Cornell University, Ithaca, New York.
Acknowledgments: The authors thank Christopher Stave for coordinating the trials search.
Potential Financial Conflicts of Interest: None of the authors have had any relationships with a pharmaceutical company that manufactures a ß-agonist or other respiratory medications. Dr. Shelley Salpeter has consulted on legal cases involving ß-agonists but has never given expert testimony and has no contracts with law firms.
Requests for Single Reprints: Shelley R. Salpeter, MD, Santa Clara Valley Medical Center, 751 South Bascom Avenue, San Jose, CA 95128; e-mail, Salpeter{at}stanford.edu.
Current Author Addresses: Drs. S. Salpeter and Ormiston: Santa Clara Valley Medical Center, 751 South Bascom Avenue, San Jose, CA 95128.
Mr. Buckley: 215 Brookwood Road, Woodside, CA 94062.
Dr. E. Salpeter: Cornell University, Space Sciences Building, Ithaca, NY 14853. REVIEW
Meta-Analysis: Effect of Long-Acting ß-Agonists on Severe Asthma Exacerbations and Asthma-Related Deaths
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  R. Beasley, F. D. Martinez, A. Hackshaw, K. F. Rabe, P. J. Sterk, and R. Djukanovic Safety of long-acting {beta}-agonists: urgent need to clear the air remains Eur. Respir. J., January 1, 2009; 33(1): 3 - 5. [Full Text] [PDF]
|
|
|
|
|
|
M. R. Sears, A. Ottosson, F. Radner, and S. Suissa Long-acting {beta}-agonists: a review of formoterol safety data from asthma clinical trials Eur. Respir. J., January 1, 2009; 33(1): 21 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. O'Byrne, I. P. Naya, A. Kallen, D. S. Postma, and P. J. Barnes Increasing Doses of Inhaled Corticosteroids Compared to Adding Long-Acting Inhaled {beta}2-Agonists in Achieving Asthma Control Chest, December 1, 2008; 134(6): 1192 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Jaeschke, P. M. O'Byrne, F. Mejza, P. Nair, W. Lesniak, J. Brozek, L. Thabane, J. Cheng, H. J. Schunemann, M. R. Sears, et al. The Safety of Long-Acting {beta}-Agonists among Patients with Asthma Using Inhaled Corticosteroids: Systematic Review and Metaanalysis Am. J. Respir. Crit. Care Med., November 15, 2008; 178(10): 1009 - 1016. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Wijesinghe, K Perrin, M Harwood, M Weatherall, and R Beasley The risk of asthma mortality with inhaled long acting {beta}-agonists Postgrad. Med. J., September 1, 2008; 84(995): 467 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Stockl, L. Le, A. S. M. Harada, and S. Zhang Use of controller medications in patients initiated on a long-acting {beta}2-adrenergic agonist before and after safety alerts Am. J. Health Syst. Pharm., August 15, 2008; 65(16): 1533 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Donohue, N. A. Hanania, C. Fogarty, S. C. Campbell, M. Rinehart, and K. Denis-Mize Long-term safety of nebulized formoterol: Results of a twelve-month open-label clinical trial Therapeutic Advances in Respiratory Disease, August 1, 2008; 2(4): 199 - 208. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Bateman, H. Nelson, J. Bousquet, K. Kral, L. Sutton, H. Ortega, and S. Yancey Meta-analysis: Effects of Adding Salmeterol to Inhaled Corticosteroids on Serious Asthma-Related Events Ann Intern Med, July 1, 2008; 149(1): 33 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. B. Weiss Drug Safety and Salmeterol: The Controversy Continues Ann Intern Med, July 1, 2008; 149(1): 56 - 57. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Wood and R. A. Stockley Editorial: Unifying the genetics, co-morbidities and management of COPD Therapeutic Advances in Respiratory Disease, June 1, 2008; 2(3): 113 - 117. [PDF]
|
|
|
|
 |
|
 S Joos, A Miksch, J Szecsenyi, B Wieseler, U Grouven, T Kaiser, and A Schneider Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review Thorax, May 1, 2008; 63(5): 453 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.F. Donohue, N.A. Hanania, K.A. Sciarappa, E. Goodwin, D.R. Grogan, R.A. Baumgartner, and J.P. Hanrahan Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: A one year evaluation of safety and tolerance Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 37 - 48. [Abstract] [PDF]
|
|
|
|
|
|
N. A. Hanania Targeting Airway Inflammation in Asthma: Current and Future Therapies Chest, April 1, 2008; 133(4): 989 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Adelsberg Review: LABAs are better than leukotriene receptor antagonists when added to inhaled corticosteroids in recurrent asthma Arch. Dis. Child. Ed. Pract., April 1, 2008; 93(2): 71 - 71. [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Salpeter Response Can Fam Physician, November 1, 2007; 53(11): 1886 - 1886. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cohen, J. Taitz, and A. Jaffe Paediatric prescribing of asthma drugs in the UK: are we sticking to the guideline? Arch. Dis. Child., October 1, 2007; 92(10): 847 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Grippi and C. Mulrow Trials That Matter: Minimizing Treatment of Mild, Persistent Asthma Ann Intern Med, September 4, 2007; 147(5): 344 - 345. [Full Text] [PDF]
|
|
|
|
|
|
D. W. Harrington and M. T. Munekata Update in General Internal Medicine Ann Intern Med, July 17, 2007; 147(2): 104 - 116. [Full Text] [PDF]
|
|
|
|
|
|
P. Ernst, A. McIvor, F. M. Ducharme, L.-P. Boulet, M. FitzGerald, K. R. Chapman, T. Bai, and for the Canadian Asthma Guideline Group Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med, November 7, 2006; 145(9): 692 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Nelson and P. M. Dorinsky Safety of long-acting beta-agonists. Ann Intern Med, November 7, 2006; 145(9): 706 - 706. [Full Text] [PDF]
|
|
|
|
|
|
D. Ryan Safety of long-acting beta-agonists. Ann Intern Med, November 7, 2006; 145(9): 707 - 707. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Lindberg Safety of long-acting beta-agonists. Ann Intern Med, November 7, 2006; 145(9): 706 - 707. [Full Text] [PDF]
|
|
|
|
|
|
S. W. Stoloff Safety of long-acting beta-agonists. Ann Intern Med, November 7, 2006; 145(9): 707 - 707. [Full Text] [PDF]
|
|
|
|
|
|
G. P. Currie Safety of long-acting beta-agonists. Ann Intern Med, November 7, 2006; 145(9): 707 - 708. [Full Text] [PDF]
|
|
|
|
|
|
J M FitzGerald and P G Gibson Asthma exacerbations {middle dot} 4: Prevention. Thorax, November 1, 2006; 61(11): 992 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J Lipchik Addition of salmeterol to usual asthma pharmacotherapy may increase respiratory related deaths or life threatening experiences Evid. Based Med., October 1, 2006; 11(5): 139 - 139. [Full Text] [PDF]
|
|
|
|
 |
|
 Effects of Long-Acting {beta}-Agonists in Children with Asthma Journal Watch Pediatrics and Adolescent Medicine, September 6, 2006; 2006(906): 1 - 1. [Full Text]
|
|
|
|
 |
|
 Long-Acting Inhaled {beta}-Agonists and Mortality Journal Watch (General), July 18, 2006; 2006(718): 3 - 3. [Full Text]
|
|
|
|
 |
|
 A. Tonks What's new in the other general journals. BMJ, June 24, 2006; 332(7556): 1500 - 1501. [Full Text] [PDF]
|
|
|
|
|
|
J. Glassroth The Role of Long-Acting {beta}-Agonists in the Management of Asthma: Analysis, Meta-Analysis, and More Analysis Ann Intern Med, June 20, 2006; 144(12): 936 - 937. [Full Text] [PDF]
|
|
Read all Rapid Responses
Article
